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Abstract: 
A challenge in modern drug therapy is to develop strategies for safer and more selective 
targeting of drug delivery in pregnancy.  Specifically, approaches are needed that would restrict 
unnecessary drug exposure to either mother or fetus.   There is evidence emerging that 
indicates the placenta does express natural transport and metabolism processes that function to 
control drug and nutrient distribution between the mother and fetus.  Further, in vitro techniques 
developed in the past ten years now provide some of the tools necessary to elucidate transport 
and metabolism processes typical of the human placenta.   As a consequence, pharmaceutical 
scientists are in a position to contribute significantly to the design and development of drugs for 
pregnancy. 
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1. Introduction 
 
 Until the thalidomide-induced birth defects occurred in the early 1960’s, physicians generally 
believed that the uterus provided a protective environment for the fetus.  Subsequently, it has become 
accepted that any chemical substance, including any therapeutic agent, administered to a mother is able 
to permeate across the placental barrier (Yaffe, 1998).   For the last four decades, the inability to control 
drug distribution across the placenta has been accepted and progress in establishing improved safety 
and selectivity of drug therapy in pregnancy has not necessarily been a priority in drug design and 
development.   There is a continuing need for many mothers to continue to receive medications for 
epilepsy, diabetes, asthma, and a variety of other medical conditions during pregnancy.  In general, drug 
use in pregnancy is on the rise over recent years (Yaffe, 1998).  This has been attributed to a lack of 
awareness of the consequences of drug and chemical exposure.  Consistent with that observation, and 
also of great concern, is the finding that drug therapy in pregnancy is now often without a specific 
rationale other than to treat the symptoms accompanying pregnancy (Yaffe, 1998).  
Comment is provided here to indicate that there is evidence suggestive of the placenta’s ability 
to control fetal exposure to drugs.  Experimental tools have also been developed in the past decade to 
investigate fundamental placental mechanisms.   Pharmaceutical scientists have the opportunity to 
employ these in vitro techniques to investigate human placental transport and metabolism mechanisms 
and play a leadership role in devising strategies to better control drug delivery in pregnancy to both 
mother and fetus.  
 
 
2. The human placental barrier  
 
Unlike other species (Enders and Blankenship, 1999), the human placental barrier is comprised 
of a single rate limiting layer of multinucleated cells, the syncytiotrophoblasts.   During placentation in 
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the human, fetal tissues erode the maternal blood vessels to attain a closer proximity to the maternal 
circulation.  Chorionic villi containing fetal blood vessels penetrate into the maternal vessels and 
establish a sinusoid in which the villi are bathed by maternal blood (Dancis, 1987; Enders and 
Blankenship, 1999).  At the cellular level, the maternal surface of the villi is covered by a layer of 
syncytiotrophoblasts with interspersed precursor cells called cytotrophoblasts or Langhans cells.  Several 
cytotrophoblasts fuse or aggregate to form a multinucleated syncytiotrophoblast (Ringler and Strauss, 
1990).  Underlying the syncytiotrophoblast is a basement membrane shared with the endothelial cells of 
the fetal capillary, however, the rate-limiting barrier for permeation across the human placenta is the 
syncytiotrophoblast layer (Ala-Kokko et al., 1993; Sibley, 1994; Enders and Blankenship, 1999).   
The predominant mechanism by which substances cross the human placental barrier is simple 
passive diffusion either transcellularly through the plasma membranes of the syncytiotrophoblast or 
paracellularly through putative aqueous channels that penetrate through the syncytiotrophoblast layer 
(Robinson et al., 1988; Ala-Kokko et al., 1993; Sibley, 1994).   As is the case with endothelia and 
epithelia, the physicochemical properties of drugs play a significant role in determining transtrophoblast 
permeation.   Molecules that are relatively lipophilic, with low protein binding, a low degree of 
ionization, and have molecular weights of less than 600 d, permeate readily across the 
syncytiotrophoblast layer (Ala-Kokko et al., 1993).   However, the actual molecular weight cutoff for 
permeation across the placental barrier has been difficult to precisely define.  It is known that peptides 
with molecular weights of ≥1000 d such as oxytocin passively permeates across the placental barrier 
with sustained maternal blood concentrations (Willis et al., 1986; Malek et al., 1996).    Several 
additional factors influence the overall placental permeation drugs and are summarized in Table 1.    
These factors include the developmental changes in the placental barrier such as pH and protein 
gradients, thickness and surface area of the barrier. 
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3. Evidence for placental control of permeability and metabolism 
The placenta has come to be known as a poor barrier to drug distribution between maternal and 
fetal circulations (Ala-Kokko et al., 1993; Dancis, 1987).  However, in a recent study with a mouse model, 
Lankas et al. (1998) have provided evidence to suggest that the placenta does limit drug or chemical 
exposure through expression of a functional multidrug resistant gene product 1 (MDR1a) or P-
glycoprotein (Pgp).  Similar expression of functional Pgp can also be demonstrated in primary cultures of 
human cytotrophoblasts which fuse to form syncytiotrophoblasts and the human cell line, BeWo, which 
is a mixture of predominantly cytotrophoblasts and a few syncytiotrophoblasts (Utoguchi et al., 1998).  
In the human  placenta there is abundant expression of the MDR1 gene throughout pregnancy (Mylona 
et al., 1996; Allikmets et al., 1998) and specifically in the cytotrophoblast (Mylona et al., 1996; Nakamura 
et al., 1997).  That placental MDR1 is functional in late human pregnancy was questioned by Macfarland 
et al. (1994) who provided some evidence that the efflux mechanism was seemingly active only early in 
pregnancy and not always was restricted to trophoblasts.  However, subsequent studies with human 
microvillar membranes of term human trophoblasts have indicated an active MDR1 (Nakamura et al., 
1997).  The obvious implications for a Pgp at the placental barrier includes the possibility that inhibitors 
of the efflux mechanism could contribute to chemically-induced teratogenesis; an outcome directly 
demonstrated when the Pgp was nonexistent in knockout animals.   A key point in understanding the 
placental barrier from the Lankas et al. (1998) study is that the placenta reduces rather than prevents 
the drug or chemical exposure of the fetus when one looks at drug concentrations in fetuses of normal 
animals compared to the fetuses of the knockout animals.  Only the knockouts exhibited birth defects.  
Therefore, one might propose that the use of drugs that are substrates for Pgp would reduce fetal drug 
exposure (Lankas et al., 1998).     
The placenta expresses a number of carrier mechanisms (e.g., amino acid transporters, 
serotonin transporters, norepinephrine transporters, organic cation transporters, extraneuronal 
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monoamine transporters, peptide transporters) that are well-characterized in other tissues and are yet, 
of unknown physiological significance in placental function.  Based on accumulating evidence, it is highly 
likely that a number of drugs of abuse (e.g., cocaine, amphetamines, nictoine, cannabinoids) achieve 
distribution across the placental barrier by utilizing both passive diffusion pathways and the carrier 
mechanisms intended for endogenous substrates (Ganapathy et al., 1999).   Consequently, drugs, drugs 
of abuse, and nutrients may all compete for carriers at the placental barrier and may result in 
circumstances where fetal exposure to drugs is enhanced at the expense of nutrients.    Thus, our 
development of a knowledge base on the function of placental transport systems is important for 
establishing an understanding of the endogenous transport mechanisms that regulate and contribute to 
fetal drug exposure (Ganapathy et al., 1999).   The characterization of trophoblast biochemical and 
transport mechanisms has had the benefit of providing a basis for the ongoing investigations directed at 
targeting gene delivery to the placenta (Parry et al., 1999).  
Although largely overlooked, the placenta also expresses cytochrome P450 (CYP) enzymes 
(Pasanen, 1999)  and peptidases (Johnson et al., 1994; Kenagy et al., 1998; Chandorkar et al., 1999).  The 
1A1/1A2 isoform is the dominant CYP present in the placenta and is inducible to significant activity 
following exposures to xenobiotics including polycyclic aromatic hydrocarbon components of tobacco 
smoke.    Additional isoforms, CYP19 (aromatase) and CYP11B (cholesterol side-chain cleaving enzyme) 
are also known to be present in the placenta throughout pregnancy.   Moreover, the placental has the 
potential to express an array of CYP isoforms depending on the length of gestation and the health of the 
mother (Pasanen, 1999).  Even less is known of peptidases, although activities of major carboxy- and 
amino-peptidases also appear to be regulated by development and components of tobacco smoke 
(Kenagy et al., 1998). 
That placental metabolism can influence fetal exposure to drugs and nutrients is not clear.  
However, polycyclic aromatic hydrocarbons are substrates for CYP1A1 and exposure to these molecules 
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correlates with low birth weights in humans and in other species (Khera et al., 1972; Allen and Barsotti, 
1976; Shum et al., 1979; Wong et al., 1985).  An implication is that placental metabolism regulates 
nutrient delivery to the fetus. Current speculation is that peptidases play a role in regulating maternal, 
fetal, and placental derived peptide hormone distribution across the placenta (Kenagy et al., 1998; 
Chandorkar et al., 1999).    The presence of a “metabolic shield” at the placental barrier raises the 
possibility of considering the design of drugs that are metabolized by the placenta thereby reducing fetal 
exposure.  This is a strategy that has been proposed in developing peptide analgesics for obstetric 
purposes (Rapaka and Porecca, 1991).  
 
4. Approaches to investigation of the human placental barrier 
 A variety of in vitro systems currently exists to evaluate the transport and metabolism processes 
of many of the significant endothelial and epithelial tissue barriers to drug delivery.  In fact, many of 
these systems are presently the primary tools at the drug design and development interface of the 
pharmaceutical industry.   A similar effort or interest in characterizing the placental barrier does not 
exist.   
The emergence of in vitro models for the human placenta within the past decade opens the 
door for investigations of drug transport and metabolism mechanisms and apply that knowledge to 
developing drugs that more selectively target either the mother or the fetus in drug therapy (Dancis and 
Liebes, 1995).  For example, human placental lobe perfusion systems have shown that mechanisms of 
placental drug transport rates and extent can be investigated in vitro (Bassily et al., 1995; Tuntland et al., 
1999; Sastry, 1999).    Human trophoblast culture systems, both primary cultures and cell lines, also 
exist, including those that form monolayers, and have been used to study uptake and transport 
mechanisms at the cellular and molecular levels (Ringler and Strauss, 1990; Yui et al., 1994; Bloxam et 
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al., 1997; Liu et al., 1997; Sastry, 1999). A point to be made is that in vitro systems are more often 
derived from mature placenta and may not represent the early pregnancy when drug exposure may be 
even more critical for the developing fetus.  Collectively, the in vitro systems have ultimately provided 
what few details we have on specific mechanisms mediating the distribution of nutrients, hormones, 
drugs, and drugs of abuse across the human placenta (Malek et al., 1996; Knipp et al., 1999; Ganapathy 
et al., 1999; Tuntland et al., 1999; Sastry, 1999).  
To conclude, the placenta does express some mechanisms that participate in regulating the 
distribution of therapeutic agents between mother and fetus. Safe and effective use of drugs in 
pregnancy will depend on the pharmaceutical scientist being able to develop approaches that take 
advantage of unique placental transport and metabolism mechanisms.  Thus, a better knowledge of 
basic placental physiology and biochemistry through the exploitation of present in vitro laboratory 
techniques, is expected lead to strategies for use of therapeutic agents in pregnancy that do not 
jeopardize the health of the fetus or the mother. 
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Table 1.  Primary factors determining drug permeation across the placental barrier.*   
Drug properties 
low degree of ionization 
lipophilicity 
low protein binding 
molecular weight ≈ 600 d or less 
Placental characteristics 
 
blood flow (intervillous maternal and fetal) – influenced by 
pathophysiological conditions and drugs 
concentration gradient of drug across the barrier 
hydrostatic gradient – slight movement toward the fetal 
compartment 
pH gradient – slightly acidic fetal compartment 
thinning and aging barrier with advancement of pregnancy 
increasing suface area with advancement of pregnancy 
developing metabolism that is largely unappreciated 
protein gradients – decreasing albumin concentration in maternal 
compartment with advancement of pregnancy, lower α1-
acid glycoprotein concentration in fetal compartment 
nutrient transporters (e.g., amino acid carriers, glucose carriers, 
monoamine carriers, etc.) – in addition to passive diffusion, 
drugs may be transported across the placenta by nutrient 
carriers 
Additional maternal and fetal factors 
fetal growth and development 
fetal metabolism 
fetal tissue binding 
maternal metabolism 
maternal health condition 
 
* Information in table summarized from Willis et al., 1986; Dancis, 1987; Ala-Kokko et al., 1993; 
Stulc and Stulcova, 1993; Moe, 1995; Ramamoorthy et al., 1995; Malek et al., 1996; Ganapathy 
et al., 1999. 
